Evidence map›Paper›PMID 33979464›Full record

Trial reportPhytotherapy research : PTR2021

Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial.

Xin-Yi Zhang, Lang Lv, Yu-Long Zhou, Liang-Dong Xie, Qin Xu, Xiao-Fan Zou, Yan Ding, Jie Tian, Jia-Liang Fan, Hai-Wei Fan and 2 more

Open access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Phytotherapy research : PTR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 10 pooled it
22.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 10 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Exploring the clinical effects ofFrontiers in pharmacology · 2025
    Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 1 country.

Xin-Yi ZhangDepartment of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Lang LvDepartment of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China.
Yu-Long ZhouDepartment of Respiratory Diseases, The Ninth Hospital of Nanchang, Nanchang, China.
Liang-Dong XieDepartment of Critical Care Medicine, The Fifth People's Hospital of Ganzhou, Ganzhou, China.
Qin XuDepartment of Respiratory Diseases, Fengcheng People's Hospital, Fengcheng, China.
Xiao-Fan ZouDepartment of Respiratory Diseases, Ji'an Central People's Hospital, Ji'an, China.
Yan DingDepartment of Respiratory Diseases, The First Affiliated Hospital of Gannan Medical University, Ganzhou, China.
Jie TianDepartment of Respiratory Diseases, The Ninth Hospital of Nanchang, Nanchang, China.
Jia-Liang FanDepartment of Respiratory Diseases, Ji'an Central People's Hospital, Ji'an, China.
Hai-Wei FanDepartment of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China.
Yi-Xi YangDepartment of Drug Research, State Key Laboratory of Innovative Natural Medicine and TCM Injections, Ganzhou, China.
Xiao-Qun YeDepartment of Respiratory Diseases, The Second Affiliated Hospital of Nanchang University, Nanchang, China.ORCID https://orcid.org/0000-0001-9682-3789
Shanghai Innovative Research Center of Traditional Chinese Medicine · CNNanchang University · CNNinth Hospital of Nanchang · CNShaanxi Provincial People's Hospital · CNFirst Affiliated Hospital of Gannan Medical University · CNGanzhou People's Hospital · CNZoucheng People's Hospital · CN

Funding

The Key Projects of Jiangxi Province 2020YBBGW0008
6 · The paper itself

Abstract

Xiyanping (XYP) is a Chinese herbal medicine used in the clinic to treat respiratory infection and pneumonia. Recent evidence identified XYP as a potential inhibitor of severe acute respiratory syndrome coronavirus 2, implying XYP as a possible treatment for the coronavirus disease 2019 (COVID-19). Here, we conducted a prospective, multicenter, open-label and randomized controlled trial to evaluate the safety and effectiveness of XYP injection in patients with mild to moderate COVID-19. We consecutively recruited 130 COVID-19 patients with mild to moderate symptoms from five study sites, and randomized them in 1:1 ratio to receive XYP injection in combination with standard therapy or receive standard supportive therapy alone. We found that XYP injection significantly reduced the time to cough relief, fever resolution and virus clearance. Less patients receiving XYP injection experienced disease progression to the severe stage during the treatment process. No severe adverse events were reported during the study. Taken together, XYP injection is safe and effective in improving the recovery of patients with mild to moderate COVID-19. However, further studies are warranted to evaluate the efficacy of XYP in an expanded cohort comprising COVID-19 patients at different disease stages.

Indexed as

COVID-19AdultDrugs, Chinese HerbalFemaleHumansInjectionsMaleMiddle AgedProspective StudiesTreatment OutcomeDrugs, Chinese Herbalandrographolidecoronavirus disease 2019 (COVID-19)SARS-CoV-2symptom resolutiontraditional Chinese medicineXiyanping

Identifiers

PMID33979464
PMCPMC8242486
OpenAlexW3161183831

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.